<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847807</url>
  </required_header>
  <id_info>
    <org_study_id>MS2304</org_study_id>
    <nct_id>NCT01847807</nct_id>
  </id_info>
  <brief_title>The Organ Protection of Astragalus in Subjects With Metabolic Syndrome</brief_title>
  <official_title>The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In
      this study, prospective randomized, controlled, parallel designed ,different doses of
      Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time
      quantitative PCR and Western Blotting to detect the index of oxidative stress
      、angiotensin-converting enzyme 2 mRNA expression and proteins.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>index of cardiac function</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ues echocardiography to measure the cardiac function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>kidney function</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>High-dose Astragalus group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 10 gram astragalus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Astragalus group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 5 gram astragalus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose Astragalus</intervention_name>
    <arm_group_label>Low-dose Astragalus group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose astagalus</intervention_name>
    <arm_group_label>High-dose Astragalus group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18 years or older, meet the diagnostic criteria of MS

          2. non-allergic with the astragalus

          3. agree to conduct clinical trials and those who signed the informed consent

        Exclusion Criteria:

          1. patients with resistant hypertension

          2. renal disease requiring dialysis

          3. heart failure NYHA ⅢorⅣ;

          4. complications of diabetes

          5. arteritis

          6. cancer

          7. thyroid disease

          8. unstable coronary heart disease

          9. peripheral vascular disease

         10. acute cerebral vascular disease11.pregnancy、 planned pregnancy

         11. patients with anti-oxidants

         12. acute infection

         13. other organic dysfunction, such as the liver, respiratory system, blood system, and
             other rheumatic diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiongying Wang, doctor</last_name>
    <phone>+869318942076</phone>
    <email>wqyconnie@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Bai, Doctor</last_name>
      <phone>+869318942376</phone>
      <email>fengbai@medmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Jing Yu</investigator_full_name>
    <investigator_title>cheif of cardiology</investigator_title>
  </responsible_party>
  <keyword>5-10 gram astragalus per day</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
